The management and outcomes of hepatocellular carcinoma in sub-Saharan Africa: a systematic review
HPB · 2024-01 · 26 (1) · 21-33
DOI: 10.1016/j.hpb.2023.09.015 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HPB, 2024-01. Verfasst von Sanju Sobnach und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Cape Town Health Sciences Faculty, Surgical Gastroenterology Unit, Groote Schuur Hospital, Cape Town, South Afri…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Harry Crossley Foundation, University of Cape Town.
Abstract (Originalsprache)
BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of mortality in sub-Saharan Africa (SSA). This systematic review aimed to appraise all population-based studies describing the management and outcomes of HCC in SSA. METHODS: A systematic review based on a search in PubMed, PubMed Central, Scopus, Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), AfricaWide and Cochrane up to June 2023 was performed. PRISMA guidelines for systematic reviews were followed. The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration no: CRD42022363955). RESULTS: Thirty-nine publications from 15 of 48 SSA countries were identified; 3989 patients were studied. The majority (74%) were male, with median ages ranging from 28 to 54 years. Chronic Hepatitis B infection was a leading aetiology and non-cirrhotic HCC was frequently reported. Curative treatment (liver resection, transplantation and ablation) was offered to 6% of the cohort. Most patients (84%) received only best supportive care (BSC), with few survivors at one year. CONCLUSION: The majority of SSA countries do not have data reporting outcomes for HCC. Most patients receive only BSC, and curative treatment is seldom available in the region. Outcomes are poor compared to high-income countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, University of Cape Town Health Sciences Faculty, Surgical Gastroenterology Unit, Groote Schuur Hospital, Cape Town, South Africa. Electronic address: sanjusobnach@yahoo.com.
- Department of Surgery, University of Cape Town Health Sciences Faculty, Surgical Gastroenterology Unit, Groote Schuur Hospital, Cape Town, South Africa.
- Division of Hepatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Department of Surgery, Windhoek Central Hospital, University of Namibia School of Medicine, Windhoek, Namibia.
- Netcare Alberton Hospital, Johannesburg, South Africa.
- Department of General and Digestive Surgery, Hôpital Militaire d'Abidjan, Abidjan, Republic of Côte d'Ivoire.
Förderung
- Harry Crossley Foundation
- University of Cape Town
Zitieren
APA
Sobnach, S., Kotze, U., Spearman, C. W., Sonderup, M., Nashidengo, P. R., Ede, C., Keli, E., Chihaka, O., Zerbini, L. F., Li, Y. J., Gandhi, K., Krige, J., & Jonas, E. (2024). The management and outcomes of hepatocellular carcinoma in sub-Saharan Africa: a systematic review. HPB, 26(1), 21-33. https://doi.org/10.1016/j.hpb.2023.09.015
Vancouver
Sobnach S, Kotze U, Spearman CW, Sonderup M, Nashidengo PR, Ede C, et al. The management and outcomes of hepatocellular carcinoma in sub-Saharan Africa: a systematic review. HPB. 2024;26(1):21-33. doi:10.1016/j.hpb.2023.09.015
BibTeX
@article{Sobnach2024,
author = {Sobnach, Sanju and Kotze, Urda and Spearman, C Wendy and Sonderup, Mark and Nashidengo, Pueya R and Ede, Chikwendu and Keli, Elie and Chihaka, Onesai and Zerbini, Luiz F and Li, Yifan J and Gandhi, Karan and Krige, Jake and Jonas, Eduard},
title = {The management and outcomes of hepatocellular carcinoma in sub-Saharan Africa: a systematic review},
journal = {HPB},
year = {2024},
volume = {26},
number = {1},
pages = {21--33},
doi = {10.1016/j.hpb.2023.09.015}
}
EUVIMED